Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 552.
Bill is filed in its originating chamber and assigned a number.
Sponsor
Jeanne Shaheen (D-NH)
Filed in the Senate.
Next: In Committee
Members of the committee(s) the bill was referred to
Bill to make insulin more affordable and accessible for Americans who need it.
The problem
Many Americans with diabetes struggle to afford insulin, which is essential medicine. Insulin prices have risen dramatically, forcing people to ration doses or skip doses.
The proposal
The bill likely aims to cap insulin costs, increase generic insulin availability, or require insurance coverage. Exact provisions require official bill text to confirm.
The impact
Diabetics would pay less for insulin. Pharmaceutical companies' revenues may decrease. Insurance companies' costs may increase or shift.
People with diabetes would spend less money on insulin, making it easier to afford this lifesaving medicine. This could prevent serious health complications from people rationing doses.
When insulin is affordable, more people take it as prescribed. This reduces diabetes complications like blindness, kidney disease, and heart problems.
People who can afford insulin need fewer emergency room visits and hospitalizations. This saves money across the entire healthcare system.
Insulin is discovered decades ago but still costs far more in America than other countries. Many see high prices as unfair to sick people.
Lower insulin prices mean pharmaceutical companies earn less money. Companies might invest less in developing new diabetes medicines and treatments.
If insurance must cover more insulin costs, insurers might raise premiums for all customers. This could hurt people who don't use insulin.
Price controls could discourage companies from making newer insulin formulas. Patients might have fewer choices of insulin types available.
Setting price caps requires careful planning to work properly. Poor design could create shortages or unintended consequences for drug supply.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.